Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Blue, my guess is Dan is on watch and will be replaced at some point in 2017 if he continues to fail to create shareholder value. He has been in the CEO position for over three years now and has raised dilutive capital in the amount of around $200 million at a weighted average cost basis of around $12. Look where the stock price is now, 25% below where his investors in aggregate have bought in. Meanwhile, the company has had some impressive clinical progress, which justifies a much higher valuation than the current status quo. The problem is when the CEO sends the signal to the market he is not aligned with shareholder interests and first and foremost is focused on paying himself excessive unearned bonus compensation, it is not too surprising that the stock has become a magnate for shorts and has remained undervalued.